ProMIS Neurosciences Inc.

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

• 13 Aug 2026ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsFinancial Post

• GAGEORGE ADAMSDirector · Executive Officer
• LALarry AltstielExecutive Officer
• HBHANS BLACKDirector
• NCNeil CashmanDirector · Executive Officer
• NCNEIL CASHMANDirector · Executive Officer
• MCMERYL CHERTOFFDirector
• JCJanet ClennettExecutive Officer
• JCJANET CLENNETTExecutive Officer
• WCWILLIAM COPELANDDirector
• PCPHILLIPE COUILLARDDirector
• GFGail FarfelExecutive Officer
• DGDaniel GeffkenExecutive Officer
• DGDaniel E. GeffkenExecutive Officer
• AGAnthony GiovinazzoDirector
• EGElliot GoldsteinDirector · Executive Officer
• EGELLIOT GOLDSTEINDirector · Executive Officer
• RGRichard GregoryDirector
• RGRICHARD GREGORYDirector
• RGROBERT GUNDELDirector · Executive Officer
• JKJohanne KaplanExecutive Officer
• PKPatrick KirwinDirector
• PKPatrick D. KirwinDirector
• PKPATRICK KIRWINDirector
• JKJames KupiecExecutive Officer
• WLWILLIAM LAMBERTDirector
• GMGavin MalenfantExecutive Officer
• JMJosh Mandel-BrehmDirector
• AMAZIZ MEKOUARDirector
• JPJAMES PARSONSExecutive Officer
• SPSteven PlotkinExecutive Officer
• JRJohannes RothDirector
• JRJOHANNES ROTHDirector
• MSMaggie ShafmasterDirector
• MSMICHAEL SONNENREICHDirector
• GSGRAHAM STRACHANDirector
• WVWALTER VON WARTBURGDirector
• NWNeil WarmaDirector
• WWWARREN WHITEHEADDirector · Executive Officer
• EWEugene WilliamsDirector · Executive Officer
• EWEUGENE WILLIAMSDirector · Executive Officer
• WWWilliam WymanDirector
• WWWILLIAM WYMANDirector

• 24 Feb 2026Antibodies To Misfolded TDP-43 And Methods Of Usegranted
• 13 Nov 2025Conformation-specific Epitopes In Alpha-synuclein, Antibodies Thereto And Methods Related Thereofapplication
• 18 Sept 2025Antibodies to Amyloid Betaapplication
• 02 Sept 2025Conformation-specific Epitopes In Alpha-synuclein, Antibodies Thereto And Methods Related Thereofgranted
• 29 Apr 2025Humanized Antibodies Binding To Amyloid-beta (a-beta)granted
• 13 Feb 2025Antibodies To Amyloid Betaapplication
• 27 Aug 2024Methods Of Reducing Amyloid Beta (a-beta) Propagation And Toxicity Induced By A-beta Oligomers Using Antibodies Specific To A-beta Oligomersgranted
• 08 Jun 2023Single Chain Antibodies And Intrabodies To Misfolded TDP-43 And Methods Of Useapplication
• 11 May 2023Antibodies To Misfolded Amyloid Betaapplication
• 14 Jul 2022Conformation-specific Epitopes In Tau, Antibodies Thereto And Methods Related Thereofapplication
• 25 Aug 2020Anti-amyloid Beta Antibodies Binding To A Cyclic Amyloid Beta Peptidegranted
• 21 Aug 2018FasR ANTIBODIES AND METHODS OF USEgranted

• 07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
• 30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
• 30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
• 29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
• 26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
• 26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.